Natural history, clinical outcome and survival of UCD patients differ depending on residual enzyme activity, gender (e.g. OTC-D), peak plasma ammonium concentrations, duration of hyperammonemia, and the age of first symptoms [3–5, 7–9, 15, 17, 18]. The gene discussed is OTC; the disease is Hyperammonemia.